Baxalta President and CEO Ludwig Hantson received almost $19 million in 2015 for running a company that was not even a year old.
José Almeida has been appointed chairman and CEO of Baxter International, the Deerfield, Ill.-based medical product company.
Baxter International said Tuesday that it's cutting about 1,400 jobs worldwide. The cuts represent 5% of the Deerfield, Ill.-based company's non-manufacturing payroll.
While most healthcare stakeholders have slowed their spending on Washington lobbying, one sector has cranked up the pressure—the medical-device industry.
Drug and medical-device maker Baxter International reported a 17% rise it its third-quarter medical products sales, a division that includes home renal-care products that are seeing brisk demand. But those strong medical product sales weren't enough to lift overall Baxter net income for the quarter.
Baxter International, the nation's leading supplier of peritoneal dialysis solution, says it can't keep up with demand and has started rationing the product, directing physicians to limit the number of new patients to whom they prescribe the treatment and reducing the size of shipments sent to...
Baxter International is selling its vaccine business to Pfizer for $635 million as it prepares to split into two companies.
Pharmaceutical and medical-device maker Hospira saw its earnings soar in the second quarter of 2014, thanks mostly to large sales of drugs that have been in short supply.
Drug and medical-device maker Baxter International reported lower profit in its second quarter, but its 2013 acquisition of Gambro helped raise worldwide sales.
Shortages of IV saline solution may continue through early next year.That's according to John Thompson, vice president of sourcing operations for Novation's medical, surgical and distribution businesses. Novation is a large, privately held group-purchasing organization based in Irving, Texas.
Baxter International agreed to pay $64 million to settle a class-action lawsuit that alleged the Deerfield, Ill.-based company and some of its competitors colluded to raise prices of plasma-based therapies.
Baxter International said today it plans to split into two companies: one for developing and marketing biopharmaceuticals, and one for medical products.